Avalo Therapeutics, Inc. (AVTX) |
|
4 -0.03 (-0.74%)
|
01-27 15:53 |
|
Open: |
3.95 |
Pre. Close: |
4.03 |
|
High:
|
4.16 |
Low:
|
3.9 |
|
Volume:
|
10,759 |
Market Cap:
|
38(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:43 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.75  One year: 6.54 |
| Support: |
Support1: 3.84 Support2: 3.2 |
| Resistance: |
Resistance1: 4.93 Resistance2: 5.59 |
| Pivot: |
4.6 |
| Moving Average: |
MA(5): 3.94 MA(20): 4.72
MA(100): 5.02 MA(250): 5.74 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 8.1  %D(3): 5.7 |
| RSI: |
RSI(14): 28.3 |
| 52-week: |
High: 11.88 Low: 0.3 |
| Average Vol(K): |
3-Month: 14 (K) 10-Days: 18 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AVTX ] has closed above bottom band by 17.8%. Bollinger Bands are 18.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.17 - 4.19 |
4.19 - 4.21 |
|
Low:
|
3.85 - 3.87 |
3.87 - 3.89 |
|
Close:
|
3.96 - 4 |
4 - 4.04 |
|
Company Description |
|
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. |
Headline News |
Mon, 23 Jan 2023
Why Evoqua Water Technologies Shares Are Trading Higher By 10 ... - Investing.com UK
Tue, 17 Jan 2023
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma - Yahoo Finance
Sat, 07 Jan 2023
Avantium N.V.'s (AMS:AVTX) market cap touched €171m last week, benefiting both individual investors who own 45% as well as institutions - Simply Wall St
Mon, 07 Nov 2022
Avalo Sells Economic Rights to Previously Out-Licensed Assets for ... - GlobeNewswire
Tue, 06 Sep 2022
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND ... - GlobeNewswire
Tue, 09 Aug 2022
These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer - TipRanks
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
9 (M) |
|
% Held by Insiders
|
3.35e+006 (%) |
|
% Held by Institutions
|
19.5 (%) |
|
Shares Short
|
34 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.612e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
-293.8 |
|
Operating Margin (%)
|
-268 |
|
Return on Assets (ttm)
|
-44.2 |
|
Return on Equity (ttm)
|
-266.4 |
|
Qtrly Rev. Growth
|
1 |
|
Gross Profit (p.s.)
|
4.67 |
|
Sales Per Share
|
1.11346e+007 |
|
EBITDA (p.s.)
|
-2.86667e+007 |
|
Qtrly Earnings Growth
|
-0.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-40 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-28.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
40800 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
